Home » Newsletters » BioWorld Science

BioWorld Science

April 29, 1998

View Archived Issues

Aspirin versus warfarin for the prevention of stroke in patients with atrial fibrillation

NeXstar: Q1 1998 highlights

Abgenix, Genentech form research collaboration

Xoma licenses protein production technology to Invitrogen for research use

Antibacterial amide derivatives of amythiamicin claimed by Japanese institute

Company Profile: Senomed

Genzyme General: Q1 1998 highlights

Genzyme Transgenics: Q1 1998 highlights

Stanford gene therapy eases multiple sclerosis symptoms in mice

Pierre Fabre synthesizes sumatriptan dimer with improved 5-HT1B/1D-agonist effects

NC-100100 enhances ultrasound imaging in phase II trial

CellPro and Corixa terminate cancer immunotherapy effort

CyDex and Allergan sign option for ophthalmic drug delivery technology

U.S. patent issues for obesity-related gene

Ligand and SmithKline Beecham expand metabolic drugs alliance

Sepracor completes norastemizole trial; additional studies planned

Pfizer claims agents for myelosuppression and for activating the immune system

Cephalosporin antibiotics developed at Roche

Takeda presents agents inhibiting PDGF activity for renal, cardiovascular disorders

Sanofi launches angiotensin II blocker in Brazil

Org-9487, a new short-acting neuromuscular blocker from Organon

U.K. market introduction for long-acting, nonsedating antihistamine

Treatment of neuropathic pain with gabapentin

RSR13 may represent novel therapeutic approach to ischemic heart disease

Connetics and Suntory sign agreement for scleroderma treatment

Nicotinic agonist shown effective in primate model of PD

CV Technologies reveals ChemBioPrint technology

New polythiophene antitumor agents for treating slow-growing tumors

Beta-blockers and sleep disturbances: the role of melatonin

Two new international trials will further explore the therapeutic benefits of Lescol

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...
DEE-lightful: Praxis’ phase II results allow stock to flex its muscle
BioWorld
Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...